Open Payments

JEFFREY A. COHEN

Type
Physician · Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
Where
Independence, OH
NPI
1104867118
Received
$125,214 in 83 records, 2019 to 2025 ($88,200 general, $37,014 research)
As principal investigator
$3,007,176 of research payments to others in 50 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment12$18,755
2025Research payment1$2,860
2024General payment3$3,755
2023General payment7$9,916
2023Research payment2$4,577
2022General payment3$6,124
2022Research payment6$5,225
2021General payment10$12,868
2021Research payment3$7,722
2020General payment5$6,480
2020Research payment5$5,667
2019General payment17$30,299
2019Research payment9$10,960

By company

CompanyRecordsAmountYears
Novartis Pharmaceuticals Corporation23$29,2182019–2025
Mylan Inc.10$18,0372019–2025
Celgene Corporation8$16,5972019–2025
Adamas Pharmaceuticals, Inc.2$14,0992019
E.R. Squibb & Sons, L.L.C.5$10,8552023–2025
Novartis Pharma AG4$7,6262019–2023
Janssen Global Services, LLC7$5,8902020–2021
F. Hoffmann-La Roche AG6$4,1482019–2020
Legend Biotech USA Inc.2$3,7752025
EMD Serono, Inc.3$3,6982022–2025
Merck KGaA1$2,6502022
GlaxoSmithKline, LLC.2$1,8922021
AstraZeneca Pharmaceuticals LP1$1,8792025
Hexal AG1$1,3002023
Biogen, Inc.1$1,2262023
Shionogi Inc1$1,2202025
Genentech, Inc.1$9002020
TG Therapeutics, Inc.1$1272025
PFIZER INC.3$512023–2024
Teva Pharmaceuticals USA, Inc.1$212019

By nature of payment

NatureRecordsAmount
Consulting Fee32$57,290
Research payment26$37,014
Travel and Lodging7$16,890
Honoraria1$7,049
Compensation for services other than consulting, including serving as faculty or as a speaker at a v6$6,471
Food and Beverage10$421
Gift1$77

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-06AstraZeneca Pharmaceuticals LP$1,879Consulting FeeCash or cash equivalent2025
2025-11-19Legend Biotech USA Inc.$3,020Consulting FeeCash or cash equivalent2025
2025-11-05Legend Biotech USA Inc.$755Consulting FeeCash or cash equivalent2025
2025-09-03Novartis Pharmaceuticals Corporation$4,331Consulting FeeCash or cash equivalentKESIMPTA Drug, Neurology2025
2025-08-04Mylan Inc.$2,132Consulting FeeCash or cash equivalentTOBI PODHALER Drug, Aminoglycosides2025
2025-07-18Shionogi Inc$1,220Consulting FeeCash or cash equivalentS-740792 Drug, Neurology2025
2025-07-15E.R. Squibb & Sons, L.L.C.$3,200Consulting FeeCash or cash equivalent2025
2025-04-28E.R. Squibb & Sons, L.L.C.$1,920Consulting FeeCash or cash equivalent2025
2025-04-10Novartis Pharmaceuticals Corporation$2,860Research paymentIn-kind items and servicesKESIMPTA Drug, NeurologyResearch Publication/Writing Support2025
2025-03-04TG Therapeutics, Inc.$127Food and BeverageIn-kind items and servicesBRIUMVI Drug, Immunology2025
2025-02-26Celgene Corporation$64Food and BeverageCash or cash equivalent2025
2025-02-26Celgene Corporation$29Food and BeverageCash or cash equivalent2025
2025-02-13EMD Serono, Inc.$77GiftIn-kind items and services2025
2024-12-17E.R. Squibb & Sons, L.L.C.$1,920Consulting FeeCash or cash equivalent2024
2024-06-07E.R. Squibb & Sons, L.L.C.$1,815Consulting FeeCash or cash equivalent2024
2024-06-06PFIZER INC.$20Food and BeverageIn-kind items and servicesPREVNAR 20 Biological, VACCINES2024
2023-12-22PFIZER INC.$17Food and BeverageIn-kind items and servicesPREVNAR 20 Biological, VACCINES2023
2023-10-24PFIZER INC.$13Food and BeverageIn-kind items and servicesPREVNAR 20 Biological, VACCINES2023
2023-10-05Biogen, Inc.$1,226Consulting FeeCash or cash equivalentTYSABRI Biological, Neurology2023
2023-09-07Hexal AG$1,300Consulting FeeCash or cash equivalent2023
2023-06-30EMD Serono, Inc.$3,360Consulting FeeCash or cash equivalentEvobrutinib2023
2023-06-13E.R. Squibb & Sons, L.L.C.$2,000Consulting FeeCash or cash equivalent2023
2023-06-13Celgene Corporation$2,000Consulting FeeCash or cash equivalent2023
2023-03-30Novartis Pharma AG$2,409Research paymentIn-kind items and servicesARZERRA Drug, HEMATOLOGYCOMB157G23022023
2023-02-15Novartis Pharmaceuticals Corporation$2,168Research paymentIn-kind items and servicesKESIMPTA Drug, NeurologyCOMB157G23012023
2022-12-07EMD Serono, Inc.$261Travel and LodgingCash or cash equivalent2022
2022-06-02Novartis Pharmaceuticals Corporation$1,770Research paymentIn-kind items and servicesARZERRA Drug, HEMATOLOGYPUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH2022
2022-06-02Novartis Pharmaceuticals Corporation$983Research paymentIn-kind items and servicesARZERRA Drug, HEMATOLOGYPUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH2022
2022-06-02Novartis Pharmaceuticals Corporation$983Research paymentIn-kind items and servicesARZERRA Drug, HEMATOLOGYPUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH2022
2022-02-24Merck KGaA$2,650Consulting FeeCash or cash equivalent2022
2022-02-09Mylan Inc.$3,213Consulting FeeCash or cash equivalent2022
2022-01-31Novartis Pharmaceuticals Corporation$705Research paymentIn-kind items and servicesARZERRA Drug, HEMATOLOGYPUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH2022
2022-01-31Novartis Pharmaceuticals Corporation$392Research paymentIn-kind items and servicesARZERRA Drug, HEMATOLOGYPUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH2022
2022-01-31Novartis Pharmaceuticals Corporation$392Research paymentIn-kind items and servicesARZERRA Drug, HEMATOLOGYPUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH2022
2021-10-21Novartis Pharmaceuticals Corporation$1,875Research paymentIn-kind items and servicesGILENYA Drug, NEUROSCIENCEA 12 MONTH PROSPECTIVE MULTICENTER TWO COHORT NONRANDOMIZED OPEN LABEL STUDY IN ADULT PATIENTS WITH RELAPSING MULTIPLE S2021
2021-08-25GlaxoSmithKline, LLC.$1,432Consulting FeeCash or cash equivalent2021
2021-08-17Novartis Pharma AG$1,699Research paymentIn-kind items and servicesARZERRA Drug, HEMATOLOGYPublication support research related2021
2021-08-05GlaxoSmithKline, LLC.$460Consulting FeeCash or cash equivalent2021
2021-07-22Celgene Corporation$3,100Consulting FeeCash or cash equivalentZEPOSIA Drug, Neuroscience2021
2021-06-02Janssen Global Services, LLC$620Consulting FeeCash or cash equivalent2021
2021-05-04Novartis Pharmaceuticals Corporation$4,148Research paymentIn-kind items and servicesARZERRA Drug, HEMATOLOGYPUBLICATION SUPPORT PROVIDED IN CONNECTION WITH ARZERRA RESEARCH2021
2021-03-24Janssen Global Services, LLC$1,860Consulting FeeCash or cash equivalent2021
2021-03-24Janssen Global Services, LLC$620Consulting FeeCash or cash equivalent2021
2021-03-24Janssen Global Services, LLC$310Consulting FeeCash or cash equivalent2021
2021-03-22Novartis Pharmaceuticals Corporation$1,276Consulting FeeCash or cash equivalentKESIMPTA Drug, NEUROSCIENCE2021
2021-03-17Novartis Pharmaceuticals Corporation$2,552Consulting FeeCash or cash equivalent2021
2021-01-07Novartis Pharmaceuticals Corporation$638Consulting FeeCash or cash equivalent2021
2020-12-23Janssen Global Services, LLC$310Consulting FeeCash or cash equivalent2020
2020-12-09Janssen Global Services, LLC$1,860Consulting FeeCash or cash equivalent2020
2020-11-11Janssen Global Services, LLC$310Consulting FeeCash or cash equivalent2020
2020-09-30F. Hoffmann-La Roche AG$676Research paymentIn-kind items and servicesOcrevus Biological, ImmunologySafety and Tolerability of shorter infusion of Ocrevus in MS patients2020
2020-09-11Novartis Pharmaceuticals Corporation$614Research paymentIn-kind items and servicesGILENYA Drug, NEUROSCIENCERESEARCH RELATED PUBLICATIONS SUPPORT2020
2020-08-03Novartis Pharma AG$3,504Research paymentIn-kind items and servicesFTY720D_GILENYA_NEUROSCIENCE Drug, NEUROSCIENCEPublication support research related2020
2020-07-15Novartis Pharmaceuticals Corporation$259Research paymentIn-kind items and servicesGILENYA Drug, NEUROSCIENCERESEARCH RELATED PUBLICATIONS SUPPORT2020
2020-06-10Genentech, Inc.$900Consulting FeeCash or cash equivalentOCREVUS Biological, Immunology2020
2020-05-12Celgene Corporation$3,100Consulting FeeCash or cash equivalentZEPOSIA Drug, Neuroscience2020
2020-02-27Novartis Pharmaceuticals Corporation$614Research paymentIn-kind items and servicesGILENYA Drug, NEUROSCIENCERESEARCH RELATED PUBLICATIONS SUPPORT2020
2019-12-20Mylan Inc.$3,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentGlatiramer Acetate Drug, Central Nervous System2019
2019-10-25Adamas Pharmaceuticals, Inc.$7,049Travel and LodgingIn-kind items and services2019
2019-10-25Adamas Pharmaceuticals, Inc.$7,049HonorariaCash or cash equivalent2019
2019-10-21Novartis Pharmaceuticals Corporation$208Research paymentIn-kind items and servicesGILENYA Drug, NEUROSCIENCERESEARCH RELATED PUBLICATIONS SUPPORT2019
2019-09-30F. Hoffmann-La Roche AG$985Compensation for services other than consulting, including serving as faculty or as a speaker at a vIn-kind items and servicesOCREVUS Biological, Immunology2019
2019-09-30F. Hoffmann-La Roche AG$371Compensation for services other than consulting, including serving as faculty or as a speaker at a vIn-kind items and servicesOCREVUS Biological, Immunology2019
2019-09-30Novartis Pharmaceuticals Corporation$208Research paymentIn-kind items and servicesGILENYA Drug, NEUROSCIENCERESEARCH RELATED PUBLICATIONS SUPPORT2019
2019-09-11Novartis Pharma AG$13Food and BeverageIn-kind items and servicesOMB157G_ARZERRA_HEMATOLOGY Drug, HEMATOLOGY2019
2019-09-10Mylan Inc.$332Travel and LodgingCash or cash equivalentGlatiramer Acetate Drug, Central Nervous System2019
2019-09-10Mylan Inc.$62Food and BeverageIn-kind items and servicesGlatiramer Acetate Drug, Central Nervous System2019
2019-09-09Mylan Inc.$331Travel and LodgingCash or cash equivalentGlatiramer Acetate Drug, Central Nervous System2019
2019-09-09Mylan Inc.$50Food and BeverageIn-kind items and servicesGlatiramer Acetate Drug, Central Nervous System2019
2019-09-09Mylan Inc.$31Travel and LodgingCash or cash equivalentGlatiramer Acetate Drug, Central Nervous System2019
2019-09-09Mylan Inc.$8Travel and LodgingCash or cash equivalentGlatiramer Acetate Drug, Central Nervous System2019
2019-09-05Mylan Inc.$8,875Travel and LodgingCash or cash equivalentGlatiramer Acetate Drug, Central Nervous System2019
2019-08-30Teva Pharmaceuticals USA, Inc.$21Food and BeverageIn-kind items and servicesAJOVY Drug, Central Nervous System2019
2019-06-30F. Hoffmann-La Roche AG$1,328Compensation for services other than consulting, including serving as faculty or as a speaker at a vIn-kind items and servicesOCREVUS Biological, Immunology2019
2019-06-30F. Hoffmann-La Roche AG$422Compensation for services other than consulting, including serving as faculty or as a speaker at a vIn-kind items and servicesOCREVUS Biological, Immunology2019
2019-05-31Novartis Pharmaceuticals Corporation$670Research paymentIn-kind items and servicesGILENYA Drug, NEUROSCIENCERESEARCH RELATED PUBLICATIONS SUPPORT2019
2019-05-09Novartis Pharmaceuticals Corporation$670Research paymentIn-kind items and servicesGILENYA Drug, NEUROSCIENCERESEARCH RELATED PUBLICATIONS SUPPORT2019
2019-03-31F. Hoffmann-La Roche AG$364Compensation for services other than consulting, including serving as faculty or as a speaker at a vIn-kind items and servicesOCREVUS Biological, Immunology2019
2019-03-01Celgene Corporation$1,144Research paymentIn-kind items and servicesRPC-1063 DrugPhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) (BMS Study Number: IM047-P14) (RPC02019
2019-02-28Novartis Pharmaceuticals Corporation$670Research paymentIn-kind items and servicesGILENYA Drug, NEUROSCIENCERESEARCH RELATED PUBLICATIONS SUPPORT2019
2019-02-28Novartis Pharmaceuticals Corporation$229Research paymentIn-kind items and servicesGILENYA Drug, NEUROSCIENCERESEARCH RELATED PUBLICATIONS SUPPORT2019
2019-01-07Celgene Corporation$3,818Research paymentIn-kind items and servicesRPC-1063 DrugA Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-2019
2019-01-07Celgene Corporation$3,342Research paymentIn-kind items and servicesRPC-1063 DrugA Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The2019

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-10-01Novartis Pharmaceuticals CorporationTHE CLEVELAND CLINIC FOUNDATION$143An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofat2025
2025-05-23E.R. Squibb & Sons, L.L.C.Cleveland Clinic Hospital$254,807A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen2025
2025-04-22E.R. Squibb & Sons, L.L.C.Cleveland Clinic Hospital$19,951A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen2025
2025-02-25Novartis Pharmaceuticals CorporationCleveland Clinic Hospital$13,529An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofat2025
2025-02-25E.R. Squibb & Sons, L.L.C.Cleveland Clinic Hospital$84,208A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen2025
2025-01-01Novartis Pharmaceuticals CorporationTHE CLEVELAND CLINIC FOUNDATION$244,795An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofat2025
2024-09-25E.R. Squibb & Sons, L.L.C.Cleveland Clinic Hospital$779CT CD19 NEX-T Phase I Esc/Exp Study for haRRMS and PPMS2024
2024-05-28Novartis Pharmaceuticals CorporationTHE CLEVELAND CLINIC FOUNDATION$261,705An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofat2024
2024-01-31Novartis Pharmaceuticals CorporationCleveland Clinic Hospital$4,790An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofat2024
2024-01-01Novartis Pharmaceuticals CorporationTHE CLEVELAND CLINIC FOUNDATION$228,755An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofat2024
2023-10-01Novartis Pharmaceuticals CorporationTHE CLEVELAND CLINIC FOUNDATION$189A Single-arm, Prospective, Multi-center Study to Explore Maintained Efficacy With Ofatumumab Therapy in Patients With Re2023
2023-09-05Novartis Pharmaceuticals CorporationTHE CLEVELAND CLINIC FOUNDATION$122,422An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofat2023
2023-01-26Novartis Pharmaceuticals CorporationCleveland Clinic Hospital$31,181An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofat2023
2023-01-01Novartis Pharmaceuticals CorporationTHE CLEVELAND CLINIC FOUNDATION$570A Single-arm, Prospective, Multi-center Study to Explore Maintained Efficacy With Ofatumumab Therapy in Patients With Re2023
2023-01-01Novartis Pharmaceuticals CorporationTHE CLEVELAND CLINIC FOUNDATION$153,789An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofat2023
2022-03-24Biogen, Inc.Cleveland Clinic Hospital$56,571A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week 2022
2022-01-25Novartis Pharmaceuticals CorporationCleveland Clinic Hospital$422,549AN OPEN LABEL SINGLE ARM MULTI CENTER EXTENSION STUDY EVALUATING LONG TERM SAFETY TOLERABILITY AND EFFECTIVENESS OF OFAT2022
2022-01-01Novartis Pharmaceuticals CorporationTHE CLEVELAND CLINIC FOUNDATION$762A SINGLE-ARM, PROSPECTIVE, MULTI-CENTER STUDY TO EXPLORE MAINTAINED EFFICACY WITH OFATUMUMAB THERAPY IN PATIENTS WITH RE2022
2021-03-17Novartis Pharmaceuticals CorporationCleveland Clinic Hospital$5,300A RANDOMIZED DOUBLE BLIND DOUBLE DUMMY PARALLEL GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF OFATUMUMAB ADMINISTERED2021
2021-01-27Novartis Pharmaceuticals CorporationCleveland Clinic Hospital$356,588AN OPEN LABEL SINGLE ARM MULTI CENTER EXTENSION STUDY EVALUATING LONG TERM SAFETY TOLERABILITY AND EFFECTIVENESS OF OFAT2021
2021-01-07Biogen, Inc.Cleveland Clinic Hospital$62,344Understanding MS patients behavior, exposure risk and MS treatment during SARS-CoV-2 pandemic at CCF/LV2021
2021-01-06Biogen, Inc.Cleveland Clinic Hospital$10,903A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switchi2021
2021-01-01Novartis Pharmaceuticals CorporationTHE CLEVELAND CLINIC FOUNDATION$825A SINGLE-ARM, PROSPECTIVE, MULTI-CENTER STUDY TO EXPLORE MAINTAINED EFFICACY WITH OFATUMUMAB THERAPY IN PATIENTS WITH RE2021
2020-12-03Biogen, Inc.Cleveland Clinic Hospital$26,719Understanding MS patients behavior, exposure risk and MS treatment during SARS-CoV-2 pandemic at CCF/LV2020
2020-11-12Mallinckrodt Hospital Products Inc.Cleveland Clinic Hospital$3,276A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP, PILOT STUDY TO ASSESS THE EFFICACY AND SAFET2020
2020-11-09GENZYME CORPORATIONCleveland Clinic Hospital$1,196A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS0342020
2020-10-01Novartis Pharmaceuticals CorporationTHE CLEVELAND CLINIC FOUNDATION$287A SINGLE-ARM, PROSPECTIVE, MULTI-CENTER STUDY TO EXPLORE MAINTAINED EFFICACY WITH OFATUMUMAB THERAPY IN PATIENTS WITH RE2020
2020-08-14Mallinckrodt Hospital Products Inc.Cleveland Clinic Hospital$4,500A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP, PILOT STUDY TO ASSESS THE EFFICACY AND SAFET2020
2020-05-04Mallinckrodt Hospital Products Inc.Cleveland Clinic Hospital$6,266A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP, PILOT STUDY TO ASSESS THE EFFICACY AND SAFET2020
2020-01-30Novartis Pharmaceuticals CorporationCleveland Clinic Hospital$200,956AN OPEN LABEL SINGLE ARM MULTI CENTER EXTENSION STUDY EVALUATING LONG TERM SAFETY TOLERABILITY AND EFFECTIVENESS OF OFAT2020
2020-01-21GENZYME CORPORATIONCleveland Clinic Hospital$972A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS0342020
2020-01-09Biogen, Inc.Cleveland Clinic Hospital$139,365A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switchi2020
2019-12-02Mallinckrodt Enterprises LLCTHE CLEVELAND CLINIC FOUNDATION$105A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP, PILOT STUDY TO ASSESS THE EFFICACY AND SAFET2019
2019-11-25GENZYME CORPORATIONWAKE FOREST UNIVERSITY HEALTH SCIENCES$798A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS0342019
2019-11-25GENZYME CORPORATIONCLEVELAND CLINIC HOSPITAL$1,201A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS0342019
2019-10-10Mallinckrodt Enterprises LLCCLEVELAND CLINIC HOSPITAL$1,317A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP, PILOT STUDY TO ASSESS THE EFFICACY AND SAFET2019
2019-09-05Mallinckrodt Enterprises LLCTHE CLEVELAND CLINIC FOUNDATION$42A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP, PILOT STUDY TO ASSESS THE EFFICACY AND SAFET2019
2019-07-22GENZYME CORPORATIONCLEVELAND CLINIC HOSPITAL$15,020A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS0342019
2019-05-30Mallinckrodt Enterprises LLCCLEVELAND CLINIC HOSPITAL$8,002A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP, PILOT STUDY TO ASSESS THE EFFICACY AND SAFET2019
2019-05-27GENZYME CORPORATIONCLEVELAND CLINIC HOSPITAL$2,400A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS0342019
2019-05-20Novartis Pharmaceuticals CorporationCLEVELAND CLINIC HOSPITAL$34,753AN OPEN LABEL SINGLE ARM MULTI CENTER EXTENSION STUDY EVALUATING LONG TERM SAFETY TOLERABILITY AND EFFECTIVENESS OF OFAT2019
2019-05-08Novartis Pharmaceuticals CorporationCLEVELAND CLINIC HOSPITAL$20,285A 12 MONTH PROSPECTIVE MULTICENTER TWO COHORT NONRANDOMIZED OPEN LABEL STUDY IN ADULT PATIENTS WITH RELAPSING MULTIPLE S2019
2019-04-23Biogen, Inc.THE CLEVELAND CLINIC FOUNDATION$90,350A Study to Evaluate Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Pa2019
2019-04-02Mallinckrodt Enterprises LLCTHE CLEVELAND CLINIC FOUNDATION$137A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP, PILOT STUDY TO ASSESS THE EFFICACY AND SAFET2019
2019-02-21Novartis Pharmaceuticals CorporationCLEVELAND CLINIC HOSPITAL$90,702A RANDOMIZED DOUBLE BLIND DOUBLE DUMMY PARALLEL GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF OFATUMUMAB ADMINISTERED2019
2019-02-18GENZYME CORPORATIONCLEVELAND CLINIC HOSPITAL$2,532A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS0342019
2019-02-15Mallinckrodt Enterprises LLCCLEVELAND CLINIC HOSPITAL$3,000A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP, PILOT STUDY TO ASSESS THE EFFICACY AND SAFET2019
2019-02-05Mallinckrodt Enterprises LLCTHE CLEVELAND CLINIC FOUNDATION$86A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP, PILOT STUDY TO ASSESS THE EFFICACY AND SAFET2019
2019-02-04Biogen, Inc.CLEVELAND CLINIC HOSPITAL$12,362A Study to Evaluate Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Pa2019
2019-01-21GENZYME CORPORATIONCLEVELAND CLINIC HOSPITAL$3,075A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS0342019

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Cuyahoga CountyIndependence city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Independence, OH, county Cuyahoga County, OH, state Ohio; placed by its city name.

MeasurePlace (city or town)
Independence, OH
County
Cuyahoga County, OH
State
Ohio
Population B010037,5341,245,87311,810,293
Population, 2020 census P17,5841,264,81711,799,448
Median age B0100248.440.439.7
Under 18 B0100119.2%20.5%22.0%
65 and over B0100125.5%19.5%18.3%
Households B110013,121554,5514,863,191
Foreign born B050023.1%7.7%5.2%
Median household income B19013$115,733$64,468$71,389
Median family income B19113$126,413$89,252$92,749
Per capita income B19301$58,711$42,747$40,552
Poverty rate B170012.4%16.1%13.3%
Unemployment rate B230251.5%6.6%4.8%
Civilian labor force B230254,068650,5775,994,779
Mean commute (minutes) B0801322.623.323.4
Bachelor's degree or higher B1500347.4%36.5%31.5%
Housing units B250013,217615,3315,292,391
Owner-occupied B2500390.4%59.4%67.2%
Renters B250039.6%40.6%32.8%
Median home value B25077$309,900$195,400$214,800
Median gross rent B25064$1,383$1,060$1,034
White, not Hispanic B0300292.4%56.5%75.8%
Black B030021.8%28.5%12.0%
Hispanic or Latino B030021.3%7.0%4.8%
Asian B030021.4%3.3%2.5%
American Indian and Alaska Native B030020.0%0.1%0.1%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Independence, OH.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.